Emerging pharmacotherapy for cancer patients with cognitive dysfunction
AuthorDavis, J; Ahlberg, FM; Berk, M; Ashley, DM; Khasraw, M
Source TitleBMC Neurology
PublisherBIOMED CENTRAL LTD
University of Melbourne Author/sBerk, Michael
Document TypeJournal Article
CitationsDavis, J., Ahlberg, F. M., Berk, M., Ashley, D. M. & Khasraw, M. (2013). Emerging pharmacotherapy for cancer patients with cognitive dysfunction. BMC NEUROLOGY, 13 (1), https://doi.org/10.1186/1471-2377-13-153.
Access StatusOpen Access
Advances in the diagnosis and multi-modality treatment of cancer have increased survival rates for many cancer types leading to an increasing load of long-term sequelae of therapy, including that of cognitive dysfunction. The cytotoxic nature of chemotherapeutic agents may also reduce neurogenesis, a key component of the physiology of memory and cognition, with ramifications for the patient's mood and other cognition disorders. Similarly radiotherapy employed as a therapeutic or prophylactic tool in the treatment of primary or metastatic disease may significantly affect cognition. A number of emerging pharmacotherapies are under investigation for the treatment of cognitive dysfunction experienced by cancer patients. Recent data from clinical trials is reviewed involving the stimulants modafinil and methylphenidate, mood stabiliser lithium, anti-Alzheimer's drugs memantine and donepezil, as well as other agents which are currently being explored within dementia, animal, and cell culture models to evaluate their use in treating cognitive dysfunction.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References